Related Experiment Video
Updated: Jun 25, 2026
14:39
Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
Published on: April 22, 2022
Plasma polyunsaturated fatty acids and age-related physical performance decline
Angela M Abbatecola1, Antonio Cherubini, Jack M Guralnik
1Department of Geriatric Medicine and Metabolic Diseases, Second University of Naples, Naples, Italy.
Rejuvenation Research
|February 7, 2009
Summary
Omega-3 polyunsaturated fatty acids (PUFA) may protect physical performance in aging adults. Higher omega-6 to omega-3 PUFA ratios are linked to a greater risk of declining physical function and slower walking speed.
Area of Science:
- Gerontology
- Nutritional Science
- Biochemistry
Background:
- Dietary patterns significantly influence physical performance during aging.
- Plasma fatty acid profiles, including saturated fatty acids (SFA) and polyunsaturated fatty acids (PUFA), are potential biomarkers for physical health.
- Understanding these associations can inform interventions to maintain mobility in older adults.
Purpose of the Study:
- To investigate the cross-sectional association between plasma fatty acids and physical performance in older adults.
- To determine if plasma fatty acids predict changes in physical performance over a 3-year period.
- To explore the relationship between specific fatty acid profiles and the risk of developing impaired physical function.
Main Methods:
- Utilized data from the InCHIANTI study, a population-based cohort of older Italians.
- Measured plasma fatty acids at baseline and assessed physical performance using the Summary Physical Performance Battery (SPPB) and 7-meter walk time at baseline and after 3 years.
- Employed multivariable regression and logistic models, adjusting for potential confounders.
Main Results:
- Participants with better physical performance (higher SPPB scores) had higher levels of total PUFA, n-3 PUFA, and n-6 PUFA, and lower SFA levels.
- Baseline n-3 PUFA levels were associated with better SPPB scores and predicted a lower risk of developing impaired lower extremity performance (OR = 0.21).
- A higher n-6/n-3 PUFA ratio was associated with a greater risk of SPPB decline (OR = 5.23) and slower walking speed.
Conclusions:
- Plasma n-3 PUFA levels, reflecting dietary intake, appear to protect against accelerated physical performance decline in aging.
- Elevated n-6/n-3 PUFA ratios are linked to an increased risk of developing poor physical performance and slower walking speed.
- These findings highlight the importance of fatty acid balance for maintaining physical function in older adults.
Related Concept Videos
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:19The Effect of Aging on Tissues
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...